Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues

Active, not recruitingOBSERVATIONAL

Enrollment

141

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

GlioblastomaMalignant Solid Neoplasm

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of tissue and blood samples

Trial Locations (1)

Thomas Jefferson University Hospital, Philadelphia

All Listed Sponsors

lead

Thomas Jefferson University

OTHER